An FDA advisory panel voted to ban formoterol (Serevent) and salmeterol (Foradil)

From JournalWatch:

FDA Panel Votes to Ban Two Drugs for Asthma

An advisory panel to the FDA voted Thursday to ban two long-acting beta agonists, Serevent (salmeterol) and Foradil (formoterol), for treating asthma in adults and children. When taken without an inhaled corticosteroid, these drugs can increase the risk for death.

Serevent and Foradil will remain on the market to treat chronic obstructive pulmonary disorders.

The panel also voted to continue allowing the use of Symbicort (formoterol plus budesonide) and Advair (salmeterol plus fluticasone). These drugs contain both long-acting beta agonists and steroids.

It is not yet known how the FDA will act on the panel’s recommendations.

Source: Briefing materials for FDA advisory panel meeting

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations. 
  • Practical tips for mental health professionals.




Are you a visual learner interested in learning psychopharmacology? Click here to get our videos